About this trial
This study looks at a treatment called LY4337713 for people with specific advanced cancers. These cancers have high levels of a protein called fibroblast activation protein (FAP). The main goals are to check how safe LY4337713 is, what side effects it may cause, and how well it works. The study will also track how the body processes this treatment. Each participant will be in the study for about 5 years.
The trial's ID number is NCT07213791. This is a Phase 1 trial, meaning it is looking at the safety and effectiveness of the treatment. It is regulated by the FDA and aims to include around 241 participants.
Who can join
This trial is for adults aged 18 and older. It is open to both men and women. Participants must have specific types of advanced cancers and have tried previous treatments. The trial team will confirm if someone is eligible to join.
Conditions
Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will receive different doses of LY4337713 through an IV. There are several groups for this trial, and each group will receive LY4337713 in different ways. Not everyone will get the same dose, as doses will be adjusted based on how well participants respond.
Where
This trial is running at 20 locations in the United States. 12 of them are currently recruiting.
BAMF Health Inc.
Grand Rapids, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Biogenix Molecular, LLC
Miami, Florida
Duke University Medical Center
Durham, North Carolina
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Indiana University (IU) School of Medicine
Indianapolis, Indiana
Massachusetts General Hospital
Boston, Massachusetts
The first 8 of 20 sites are listed here. The registry record has the full list.